Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Platinum/Etoposide in Advanced Extrapulmonary Neuroendocrine Carcinomas
NCT05058651Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in extrapulmonary neuroendocrine carcinoma (EPNEC) comparing Arm I (atezolizumab, platinum drug, etoposide), Arm II (atezolizumab, platinum drug, etoposide, observation) and Arm III (platinum drug, etoposide, observation) (3 arms). Primary endpoint: Overall Survival at 5 years. Started Jun 2022; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT05058651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058651.